Historique
Périodique
Pharmacotherapy of comorbid mood, anxiety, and substance use disorders
(Pharmacothérapie d'une comorbidité de troubles liés à l'abus de substances psychoactives et de troubles de l'humeur ou d'anxiété)
Auteur(s) :
BRADY, K. T. ;
VERDUIN, M. L.
Année
2005
Page(s) :
2021-2041
Langue(s) :
Anglais
Refs biblio. :
102
Domaine :
Plusieurs produits
Thésaurus mots-clés
ANXIETE
;
TROUBLES DE L'HUMEUR
;
DEPRESSION
;
COMORBIDITE
;
NEUROBIOLOGIE
;
PHARMACOTHERAPIE
;
MEDICAMENTS
;
EFFICACITE
;
ABUS
Note générale :
Substance Use and Misuse, 2005, 40, (13-14), 2021-2041
Résumé :
ENGLISH :
Mood and anxiety disorders commonly co-occur with .substance use disorders. Exploration of the neurobiology of substance use disorders and mood and anxiety disorders have found that the neural circuitry in mood, anxiety, and substance use disorders is clearly overlapping. These discoveries have encouraged the exploration of a number of pharmacotherapeutic agents in the treatment of co-occurring mood, anxiety, and substance use disorders. In this article, recent data on the pharmacotherapeutic treatment of mood and anxiety disorders in individuals with substance use disorders are reviewed. Some of the barriers to the use of pharmacotherapy in individuals with substance use disorders are discussed. (Editor's abstract.)
Affiliation :
Institute of Psychiatry, Clinical Neuroscience, Medical University of South Carolina, 67 President Street, PO Box 250861 Charleston, SC 29425. E-mail : bradykmusc.edu
Etats-Unis. United States.
Etats-Unis. United States.